oxonic acid has been researched along with Lassitude in 15 studies
Oxonic Acid: Antagonist of urate oxidase.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Here, we reported an interim analysis of feasibility and safety in the first 10 cases of 30 cases in a phase II trial of intravenous and intraperitoneal paclitaxel combined with S-1 for gemcitabine-refractory pancreatic cancer with malignant ascites." | 9.19 | Intravenous and intraperitoneal paclitaxel with S-1 for refractory pancreatic cancer with malignant ascites: an interim analysis. ( Hamada, T; Hirano, K; Ijichi, H; Isayama, H; Ishigami, H; Kawakubo, K; Kitayama, J; Kogure, H; Koike, K; Miyabayashi, K; Mizuno, S; Mohri, D; Nakai, Y; Sasahira, N; Sasaki, T; Tada, M; Takahara, N; Tateishi, K; Uchino, R; Watanabe, T; Yamaguchi, H; Yamamoto, N; Yamashita, H, 2014) |
| "Gemcitabine has been standard of care in advanced pancreatic adenocarcinomas (PC) for almost two decades." | 7.88 | S-1 (Teysuno) and gemcitabine in Caucasian patients with unresectable pancreatic adenocarcinoma. ( Bjerregaard, JK; Ejlsmark, MW; Jensen, HA; Krogh, M; Pfeiffer, P; Schonnemann, KR; Winther, SB, 2018) |
| "Here, we reported an interim analysis of feasibility and safety in the first 10 cases of 30 cases in a phase II trial of intravenous and intraperitoneal paclitaxel combined with S-1 for gemcitabine-refractory pancreatic cancer with malignant ascites." | 5.19 | Intravenous and intraperitoneal paclitaxel with S-1 for refractory pancreatic cancer with malignant ascites: an interim analysis. ( Hamada, T; Hirano, K; Ijichi, H; Isayama, H; Ishigami, H; Kawakubo, K; Kitayama, J; Kogure, H; Koike, K; Miyabayashi, K; Mizuno, S; Mohri, D; Nakai, Y; Sasahira, N; Sasaki, T; Tada, M; Takahara, N; Tateishi, K; Uchino, R; Watanabe, T; Yamaguchi, H; Yamamoto, N; Yamashita, H, 2014) |
| "Gemcitabine has been standard of care in advanced pancreatic adenocarcinomas (PC) for almost two decades." | 3.88 | S-1 (Teysuno) and gemcitabine in Caucasian patients with unresectable pancreatic adenocarcinoma. ( Bjerregaard, JK; Ejlsmark, MW; Jensen, HA; Krogh, M; Pfeiffer, P; Schonnemann, KR; Winther, SB, 2018) |
| "Patients with stage III gastric cancer who underwent D2 gastrectomy were enrolled." | 3.01 | Phase II feasibility study of adjuvant chemotherapy with docetaxel/cisplatin/S-1 followed by S-1 for stage III gastric cancer. ( Hirahara, N; Hyakudomi, R; Ishitobi, K; Kaji, S; Matsubara, T; Tajima, Y; Takai, K; Uchida, Y; Yamamoto, T, 2021) |
| "Unresectable advanced hepatocellular carcinoma is a heterogeneous disease, for which sorafenib is the first targeted agent approved for first-line therapy, and treatment options for patients with sorafenib-refractory advanced hepatocellular carcinoma are limited." | 2.84 | S-1 versus placebo in patients with sorafenib-refractory advanced hepatocellular carcinoma (S-CUBE): a randomised, double-blind, multicentre, phase 3 trial. ( Date, Y; Fang, X; Furuse, J; Hidaka, H; Ikeda, M; Kaneko, S; Kawazoe, S; Kudo, M; Moriguchi, M; Numata, K; Ohkawa, S; Okusaka, T; Sato, Y; Takeuchi, M; Tanaka, H, 2017) |
| "The primary objective of this Phase I study was to assess the safety and tolerability of the vascular endothelial growth factor signalling inhibitor cediranib in combination with cisplatin plus an oral fluoropyrimidine, in Japanese patients with previously untreated advanced gastric cancer." | 2.77 | Phase I study of cediranib in combination with cisplatin plus fluoropyrimidine (S-1 or capecitabine) in Japanese patients with previously untreated advanced gastric cancer. ( Boku, N; Brown, KH; Hayashi, H; Muro, K; Nakajima, TE; Satoh, T; Shi, X; Shimada, Y; Takahari, D; Taku, K; Yamada, Y, 2012) |
| "Although fatigue was the most frequently encountered toxicity safety profiles were generally predictable and manageable." | 2.73 | Mitomycin C plus S-1 as second-line therapy in patients with advanced gastric cancer: a noncomparative phase II study. ( Cho, EK; Chung, M; Hong, J; Kim, YS; Lee, JH; Lee, WK; Nam, E; Park, J; Park, SH; Shin, DB, 2008) |
| "Irinotecan was given intravenously over the course of 90 min on day 1 and S-1 was given orally from days 1 to 14 of a 21-day cycle." | 2.71 | Phase I study of irinotecan and S-1 combination therapy in patients with metastatic gastric cancer. ( Arai, T; Goto, A; Hamaguchi, T; Muro, K; Shimada, Y; Shirao, K; Ura, T; Yamada, Y; Yasui, H, 2003) |
| " Severe adverse events were observed in 22 patients (91." | 1.42 | Feasibility and toxicity of adjuvant chemotherapy using S-1 granules for local advanced squamous cell carcinoma of the head and neck. ( Honda, K; Ishikawa, K; Sato, T; Suzuki, S; Yamazaki, K, 2015) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (13.33) | 29.6817 |
| 2010's | 12 (80.00) | 24.3611 |
| 2020's | 1 (6.67) | 2.80 |
| Authors | Studies |
|---|---|
| Hirahara, N | 1 |
| Matsubara, T | 1 |
| Kaji, S | 1 |
| Yamamoto, T | 1 |
| Hyakudomi, R | 1 |
| Takai, K | 1 |
| Ishitobi, K | 1 |
| Uchida, Y | 1 |
| Tajima, Y | 1 |
| Kudo, M | 1 |
| Moriguchi, M | 1 |
| Numata, K | 1 |
| Hidaka, H | 1 |
| Tanaka, H | 1 |
| Ikeda, M | 1 |
| Kawazoe, S | 1 |
| Ohkawa, S | 1 |
| Sato, Y | 1 |
| Kaneko, S | 1 |
| Furuse, J | 1 |
| Takeuchi, M | 2 |
| Fang, X | 1 |
| Date, Y | 1 |
| Okusaka, T | 1 |
| Winther, SB | 2 |
| Bjerregaard, JK | 1 |
| Schonnemann, KR | 1 |
| Ejlsmark, MW | 1 |
| Krogh, M | 2 |
| Jensen, HA | 2 |
| Pfeiffer, P | 2 |
| Takahara, N | 1 |
| Isayama, H | 1 |
| Nakai, Y | 1 |
| Sasaki, T | 2 |
| Ishigami, H | 1 |
| Yamashita, H | 1 |
| Yamaguchi, H | 1 |
| Hamada, T | 2 |
| Uchino, R | 1 |
| Mizuno, S | 1 |
| Miyabayashi, K | 1 |
| Mohri, D | 1 |
| Kawakubo, K | 1 |
| Kogure, H | 1 |
| Yamamoto, N | 1 |
| Sasahira, N | 1 |
| Hirano, K | 1 |
| Ijichi, H | 1 |
| Tateishi, K | 1 |
| Tada, M | 1 |
| Kitayama, J | 1 |
| Watanabe, T | 2 |
| Koike, K | 1 |
| Suzuki, S | 1 |
| Honda, K | 1 |
| Sato, T | 1 |
| Yamazaki, K | 2 |
| Ishikawa, K | 1 |
| Takashima, T | 1 |
| Mukai, H | 1 |
| Hara, F | 1 |
| Matsubara, N | 1 |
| Saito, T | 1 |
| Takano, T | 1 |
| Park, Y | 1 |
| Toyama, T | 1 |
| Hozumi, Y | 1 |
| Tsurutani, J | 1 |
| Imoto, S | 1 |
| Sagara, Y | 1 |
| Nishimura, R | 1 |
| Shimozuma, K | 1 |
| Ohashi, Y | 1 |
| Zubcevic, K | 1 |
| Qvortrup, C | 1 |
| Vestermark, LW | 1 |
| Sorbye, H | 1 |
| Park, SH | 1 |
| Kim, YS | 1 |
| Hong, J | 1 |
| Park, J | 1 |
| Nam, E | 1 |
| Cho, EK | 1 |
| Shin, DB | 1 |
| Lee, JH | 1 |
| Lee, WK | 1 |
| Chung, M | 1 |
| Oh, DY | 1 |
| Cha, Y | 1 |
| Choi, IS | 2 |
| Yoon, SY | 1 |
| Choi, IK | 1 |
| Kim, JH | 2 |
| Oh, SC | 1 |
| Kim, CD | 1 |
| Kim, JS | 1 |
| Bang, YJ | 1 |
| Kim, YH | 1 |
| Koizumi, W | 1 |
| Akiya, T | 1 |
| Sato, A | 1 |
| Sakuyama, T | 1 |
| Sasaki, E | 1 |
| Tomidokoro, T | 1 |
| Fujimori, M | 1 |
| Kikuchi, Y | 1 |
| Shimada, K | 1 |
| Mine, T | 1 |
| Yamaguchi, K | 1 |
| Kurihara, M | 1 |
| Lee, KW | 1 |
| Kim, KH | 1 |
| Kim, YJ | 1 |
| Lee, JS | 1 |
| Tsushima, T | 1 |
| Hironaka, S | 1 |
| Boku, N | 2 |
| Machida, N | 1 |
| Yasui, H | 2 |
| Taku, K | 2 |
| Fukutomi, A | 1 |
| Onozawa, Y | 1 |
| Satoh, T | 1 |
| Yamada, Y | 2 |
| Muro, K | 2 |
| Hayashi, H | 1 |
| Shimada, Y | 2 |
| Takahari, D | 1 |
| Nakajima, TE | 1 |
| Shi, X | 1 |
| Brown, KH | 1 |
| Kimura, Y | 1 |
| Yano, H | 1 |
| Imamura, H | 1 |
| Fujitani, K | 1 |
| Imano, M | 1 |
| Tokunaga, Y | 1 |
| Matsuoka, M | 1 |
| Kurokawa, Y | 1 |
| Shimokawa, T | 1 |
| Takiuchi, H | 1 |
| Tsujinaka, T | 1 |
| Furukawa, H | 1 |
| Goto, A | 1 |
| Arai, T | 1 |
| Ura, T | 1 |
| Hamaguchi, T | 1 |
| Shirao, K | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Phase II Trial of Cisplatin Combined With Oral TS-1 in Patients With Advanced Solid Tumors With Different Degrees of Liver Dysfunction[NCT03519074] | Phase 2 | 48 participants (Anticipated) | Interventional | 2016-07-22 | Recruiting | ||
| Feasibility of Switching Fluoropyrimidine Due to Cardiotoxicity in Patients With Solid Tumors: A Retrospective, International and Non-interventional Study[NCT04260269] | 200 participants (Anticipated) | Observational | 2018-06-01 | Enrolling by invitation | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
13 trials available for oxonic acid and Lassitude
| Article | Year |
|---|---|
Phase II feasibility study of adjuvant chemotherapy with docetaxel/cisplatin/S-1 followed by S-1 for stage III gastric cancer.
Topics: Adenocarcinoma; Aged; Anemia; Anorexia; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy | 2021 |
S-1 versus placebo in patients with sorafenib-refractory advanced hepatocellular carcinoma (S-CUBE): a randomised, double-blind, multicentre, phase 3 trial.
Topics: Aged; Antimetabolites, Antineoplastic; Carcinoma, Hepatocellular; Diarrhea; Double-Blind Method; Dru | 2017 |
Intravenous and intraperitoneal paclitaxel with S-1 for refractory pancreatic cancer with malignant ascites: an interim analysis.
Topics: Adenocarcinoma; Aged; Alopecia; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherap | 2014 |
Taxanes versus S-1 as the first-line chemotherapy for metastatic breast cancer (SELECT BC): an open-label, non-inferiority, randomised phase 3 trial.
Topics: Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Disease | 2016 |
Experience with S-1 in older Caucasian patients with metastatic colorectal cancer (mCRC): Findings from an observational chart review.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Ne | 2016 |
Mitomycin C plus S-1 as second-line therapy in patients with advanced gastric cancer: a noncomparative phase II study.
Topics: Adult; Aged; Anemia, Hemolytic; Antineoplastic Combined Chemotherapy Protocols; Disease Progression; | 2008 |
A multicenter phase II study of gemcitabine and S-1 combination chemotherapy in patients with unresectable pancreatic cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Drug Combinations; Fatig | 2010 |
Phase II study of S-1 as first-line treatment for elderly patients over 75 years of age with advanced gastric cancer: the Tokyo Cooperative Oncology Group study.
Topics: Aged; Aged, 80 and over; Anorexia; Antimetabolites, Antineoplastic; Drug Combinations; Fatigue; Fema | 2010 |
Three-weekly S-1 plus cisplatin chemotherapy as first-line treatment for advanced gastric cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Disease-Free | 2010 |
Safety and efficacy of S-1 monotherapy in elderly patients with advanced gastric cancer.
Topics: Adenocarcinoma; Administration, Oral; Age Factors; Aged; Aged, 80 and over; Anemia; Anorexia; Antime | 2010 |
Phase I study of cediranib in combination with cisplatin plus fluoropyrimidine (S-1 or capecitabine) in Japanese patients with previously untreated advanced gastric cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Appetite; Area Under Curve; Asian Peopl | 2012 |
A phase I study of triplet combination chemotherapy of paclitaxel, cisplatin and S-1 in patients with advanced gastric cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Drug Administration Schedule | 2013 |
Phase I study of irinotecan and S-1 combination therapy in patients with metastatic gastric cancer.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Dru | 2003 |
2 other studies available for oxonic acid and Lassitude
| Article | Year |
|---|---|
S-1 (Teysuno) and gemcitabine in Caucasian patients with unresectable pancreatic adenocarcinoma.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Coho | 2018 |
Feasibility and toxicity of adjuvant chemotherapy using S-1 granules for local advanced squamous cell carcinoma of the head and neck.
Topics: Administration, Oral; Adult; Aged; Antimetabolites, Antineoplastic; Carcinoma, Squamous Cell; Chemot | 2015 |